RE:RE:RE:RE:Strong Cash Position at exit 2020In the search for a Canada-based public pharma company looking for tax losses, all roads lead to Laval and stop at Bausch Health. But Bausch just can't stand the current Cipher CEO. As much as business is business, Mull's personality and perceived intent are both strong deterrents to resuming discussion. It's not just Bausch in the camp who don't like Craig. He has wasted the time of more than a few potential partners, acquirers, and suitors and he will have challenges bringing any serious figures back to the table. This observation will probably cause his defenders to resume squealing, but it's incontrovertable.